Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John E Murphy

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Journal of the American Academy of Nurse Practitioners|April 15, 2011
Medical, nursing, and pharmacy students' ability to recognize potential drug-drug interactions: a comparison of healthcare professional studentsTerri L Warholak, Lisa E Hines, Mi Chi Song, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 10, 2007
Potential drug-drug interactions within Veterans Affairs medical centersMaysaa Mahmood, Daniel C Malone, Grant H Skrepnek, et al.
Drug Safety|May 20, 2008
Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribersYu Ko, Daniel C Malone, Grant H Skrepnek, et al.
Blood|October 22, 2014
Noncovalent stabilization of the factor VIII A2 domain enhances efficacy in hemophilia A mouse vascular injury modelsLilley Leong, Derek Sim, Chandra Patel, et al.
Thrombosis and Haemostasis|June 12, 2024
Field Study and Correlative Studies of Factor IX Variant FIX-R338L in Participants Treated with Fidanacogene ElaparvovecDebra D Pittman, Charles Carrieri, Holly Soares, et al.
Journal of Pharmaceutical Sciences|March 25, 2018
Translational Pharmacokinetic/Pharmacodynamic Characterization and Target-Mediated Drug Disposition Modeling of an Anti-Tissue Factor Pathway Inhibitor Antibody, PF-06741086Chuenlei Parng, Pratap Singh, Debra D Pittman, et al.
Journal of Thrombosis and Haemostasis : JTH|February 26, 2021
Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-PaduaMary M Robinson, Lindsey A George, Marcus E Carr, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 24, 2019
Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmasSunita Patel-Hett, Erika J Martin, Bassem M Mohammed, et al.
Pharmacotherapy|April 23, 2014
The need for PGY2-trained clinical pharmacy specialistsKelly R Ragucci, Cindy L O'Bryant, Kristin Bova Campbell, et al.
Blood|March 3, 2010
Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatmentBaisong Mei, Clark Pan, Haiyan Jiang, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Journal of the American Academy of Nurse Practitioners|April 15, 2011
Medical, nursing, and pharmacy students' ability to recognize potential drug-drug interactions: a comparison of healthcare professional studentsTerri L Warholak, Lisa E Hines, Mi Chi Song, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 10, 2007
Potential drug-drug interactions within Veterans Affairs medical centersMaysaa Mahmood, Daniel C Malone, Grant H Skrepnek, et al.
Drug Safety|May 20, 2008
Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribersYu Ko, Daniel C Malone, Grant H Skrepnek, et al.
Blood|October 22, 2014
Noncovalent stabilization of the factor VIII A2 domain enhances efficacy in hemophilia A mouse vascular injury modelsLilley Leong, Derek Sim, Chandra Patel, et al.
Thrombosis and Haemostasis|June 12, 2024
Field Study and Correlative Studies of Factor IX Variant FIX-R338L in Participants Treated with Fidanacogene ElaparvovecDebra D Pittman, Charles Carrieri, Holly Soares, et al.
Journal of Pharmaceutical Sciences|March 25, 2018
Translational Pharmacokinetic/Pharmacodynamic Characterization and Target-Mediated Drug Disposition Modeling of an Anti-Tissue Factor Pathway Inhibitor Antibody, PF-06741086Chuenlei Parng, Pratap Singh, Debra D Pittman, et al.
Journal of Thrombosis and Haemostasis : JTH|February 26, 2021
Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-PaduaMary M Robinson, Lindsey A George, Marcus E Carr, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 24, 2019
Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmasSunita Patel-Hett, Erika J Martin, Bassem M Mohammed, et al.
Pharmacotherapy|April 23, 2014
The need for PGY2-trained clinical pharmacy specialistsKelly R Ragucci, Cindy L O'Bryant, Kristin Bova Campbell, et al.
Blood|March 3, 2010
Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatmentBaisong Mei, Clark Pan, Haiyan Jiang, et al.
Pageof 6